




FIG. 1

SEQ. ID NO. 1 (trastuzumab heavy chain):

EVQLVESGGGLVQPGGSLRLSCAASG FNIKDTYIHVVVRQAPGKGLEWVARIYPTNGYT
RYADSVKGRFTISADTSKNTAYLQMNSLR AEDTAVYYCSRWGGDGFYAMDYWGQGT
LVTVSSASTKGPSVFPLAPSSKSTSGGT AALGCLVKDYFPEPVTVSWNSGALTSGVHTFP
AVLQSSGLYSLSSVTVPSSSLGTQTYIC NVNHKPSNTKVDKKVEPKSCDKTHTCTPCPA
PELLGGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKE YCKVSNKALPAPIEKTISKAKGQPREPQV
YTLPPSREEMTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTTPVLDSDGSFFLYS
KLTVDKSRWQQGNVVFSCSVMHEALHNH YTKSLSLSPG

SEQ. ID NO. 2 (trastuzumab light chain):

DIQMTQSPSSLSASVGDRVTITCRASQD VNTAVAWYQQKPGKAPKLLIYSASFLEYSGVP
SRFSGSRSGTDFLTISSLQPEDFATYYC QQHYYTTPPTFGQGTKVEIKRTVAAPSVFIFPPS
DEQLKSGTASVVCLLNNFYPREAKVQWK VDNALQSGNSQESVTEQDSKDDSTYSLSSTL
TLSKADYEKHKVYACEVTHQGLSSPVTKS FNRGEC

SEQ. ID NO. 3 (trastuzumab light chain variable domain):

DIQMTQSPSSLSASVGDRVTITCRASQD VNTAVAWYQQKPGKAPKLLIYSASFLESGVPS
RFSGSRSGTDFLTISSLQPEDFATYYC QQHYYTTPPTFGQGTKVEIKRT

SEQ. ID NO. 4 (trastuzumab heavy chain variable domain):

EVQLVESGGGLVQPGGSLRLSCAASG FNIKDTYIHVVVRQAPGKGLEWVARIYPTNGYT
RYADSVKGRFTISADTSKNTAYLQMNSLR AEDTAVYYCSRWGGDGFYAMDYWGQGT
LVTVSS

FIG. 2

3/9




FIG. 3A




FIG. 3B

4/9




FIG. 3C

Group Mean +/- SEM
n=10/group




FIG. 4A





FIG. 4B

6/9


Effect on Tumor Growth of Tucatinib and Trastuzumab
in Gastric Cancer PDX GXA 3038
Group Mean (n=10) Tumor Volume + SD



- ✕ Vehicle Control
- ◆ Tucatinib: 50 mg/kg/dose, PO, BID x 28
- Trastuzumab: 20 mg/kg/dose, IP, Q3D x 9
- ▲ Tucatinib + Trastuzumab

FIG. 5A

Effect on Tumor Growth of Tucatinib and Trastuzumab
in Gastric Cancer PDX GXA 3039
Group Mean (n=7) Tumor Volume + SD



- ✕ Vehicle Control
- ◆ Tucatinib: 50 mg/kg/dose, PO, BID x 28
- Trastuzumab: 20 mg/kg/dose, IP, Q3D x 9
- ▲ Tucatinib + Trastuzumab

FIG. 5B

7/9




FIG. 5C

8/9





FIG. 6

9/9

Efficacy of Tucatinib and Trastuzumab
in Calu-3 Her2+ NSCLC Xenograft Model
Group Mean Tumor Volume




- ✕ Vehicle Control
- ◆ Tucatinib 83% TGI
- Trastuzumab 86% TGI
- ▲ Tucatinib + Trastuzumab 100% TGI

Group Mean +/- SEM
n=10/group

FIG. 7A

Efficacy of Tucatinib and Trastuzumab
in NCI-H2170 Her2+ NSCLC Xenograft Model
Group Mean Tumor Volume



- ✕ Vehicle Control
- ◆ Tucatinib
- Trastuzumab
- ▲ Tucatinib + Trastuzumab

Group Mean +/- SEM
n=10/group

FIG. 7B